NCT04200040 - A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

August 27, 2017

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

OrienX010 injection

"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."

DRUG

Dacarbazine (DTIC)

Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing